Chris Longshaw is a Senior Director in the European Scientific Affairs group at Shionogi BV, where he has worked since 2017, supporting the infectious disease portfolio.

Chris has experience working in European and national Medical Affairs for a range of pharmaceutical companies, including large Pharma (Wyeth/Pfizer), medium (Astellas) and small (Basilea). He helped develop and commercialize many anti-infective products, including cefiderocol, ceftobiprole, fidaxomicin, isavuconazole, micafungin and telavancin. Early in his career, Chris worked in anti-infective discovery for Cubist Pharmaceuticals on a joint EU project (COINS) to prevent the spread of antimicrobial resistance via inhibition of conjugative plasmid transfer. He also worked for Syngenta BioPharma screening for novel medicinal antimicrobials from agrochemical libraries.

Chris has co-authored numerous peer-reviewed publications, including in high-impact journals such as the Lancet Infectious Disease and Eurosurveillance and was one of the EFPIA co-leads within the Innovative Medicines Initiative/New Drugs 4 Bad Bugs project, DRIVE-AB. He is a member of the Scientific Committee for Antibiotic Research UK and the council for the British Society for Antimicrobial Chemotherapy and an industry representative for the Resistance Surveillance Working Group before taking up the office of Honorary Treasurer in 2018.

Chris studied Medical Microbiology at Leeds University, UK, gaining his PhD for work on the regulation of colonization factors in coagulase-negative staphylococci.